Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070241 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL5071157 | 0.85 | CCR5 (0.37) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL5071154 | 0.85 | CCR5 (0.37) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL14174939 | 0.83 | HSD11B1 (0.33) | SMN1; SMN2ALDH1A1KMT2AHSD11B1POLB | |
| SCHEMBL1721875 | 0.80 | HSD11B1 (0.40) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL1721874 | 0.80 | HSD11B1 (0.40) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL2244521 | 0.80 | HSD11B1 (0.40) | SMN1; SMN2ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL15777723 | 0.78 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL15777724 | 0.78 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL21107301 | 0.76 | KAT6A (0.33) | NR1H4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1585481-A2 | PYRAZOLOPYRIMIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004064721-A2 | A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | KCNJ2, KCNN2, KCNH2 | SMN1; SMN2 1291/4885ALDH1A1 2470/4885GAA 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.